Business Context and Reporting Period
This Form 10-Q is a combined quarterly report for Prestige Brands Holdings, Inc. (PBH) and its indirect wholly-owned subsidiary, Prestige Brands International, LLC (PBI). PBH is a holding company with no ongoing operations; PBI is the parent guarantor of the company's debt and the indirect parent of the operating subsidiaries. The company markets, sells, and distributes over-the-counter (OTC) drugs, personal care, and household cleaning brands primarily in the United States and Canada. The reporting period covers the three and six months ended September 30, 2006.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 30, 2006 | 6 Months Ended Sep 30, 2006 |
|---|---|---|
| Total Revenues | $84,551 | $160,474 |
| Net Sales | $84,033 | $159,600 |
| Gross Profit | $43,292 | $82,890 |
| Gross Margin | 51.2% | 51.7% |
| Operating Income | $24,166 | $47,515 |
| Net Income | $8,784 | $17,040 |
| Diluted EPS | $0.18 | $0.34 |
| Operating Cash Flow (6mo) | $42,734 | |
| Total Debt (Long-term + Current) | $489,765 | |
| Cash and Equivalents | $10,508 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 15.3% ($11.2 million) for the quarter and 17.3% ($23.7 million) for the six months compared to the prior year periods. Excluding acquisitions made in late 2005 (Chore Boy and The Doctor's), organic revenue growth was 6.7% for the quarter and 7.5% for the six months.
- Segment Performance:
- Over-the-Counter Drug: Revenues increased 13.5% (quarter) and 15.8% (six months), driven by strong gains in Clear Eyes, Little Remedies, Chloraseptic, Murine, and Compound W.
- Household Cleaning: Revenues increased 23.7% (quarter) and 27.6% (six months), largely due to the Chore Boy acquisition and growth in Comet and Spic and Span.
- Personal Care: Revenues declined 3.9% (quarter) and 9.0% (six months) due to continued declines in Cutex, Denorex, and Prell.
- Profitability: Net income increased 19.1% for the quarter and 28.1% for the six months. Operating income rose 16.0% (quarter) and 21.6% (six months).
- Acquisition Activity: On September 21, 2006, the company acquired Wartner USA B.V. for approximately $35.1 million (including contingent payments), adding the Wartner brand to the OTC segment.
- Interest Expense: Net interest expense increased 12.4% for the quarter and 13.7% for the six months due to rising interest rates on variable-rate debt (average cost of funds rose from 7.0% to 8.0% for the quarter).
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management expects the Wartner brand to benefit from targeted marketing and the company's outsourcing model. The company anticipates continued growth in OTC and Household Cleaning segments but notes ongoing declines in the Personal Care segment.
- Liquidity: The company maintains $60.0 million of available borrowing capacity under its Revolving Credit Facility and $200.0 million under its Tranche B Term Loan Facility. Management believes cash flows and available borrowings are sufficient for the next 12 months.
- Legal Proceedings:
- Securities Class Action: A consolidated lawsuit regarding the 2005 IPO remains pending, though claims under the Securities Exchange Act of 1934 were dismissed in July 2006. The company cannot estimate potential losses.
- Similasan Litigation: Similasan Corporation sued the company alleging trademark infringement and breach of confidentiality regarding Murine products. The company intends to vigorously defend.
- OraSure Technologies: OraSure sought a preliminary injunction to stop sales of Wartner products; the motion was denied on October 30, 2006. The dispute is subject to mediation and arbitration.
- Risk Factors: Key risks include dependence on a limited number of customers (one customer accounted for 24.1% of sales in the quarter), reliance on third-party manufacturers (top 10 manufacturers account for 78% of sales), and potential impairment of goodwill and intangible assets if sales decline.
Investor Verification Checklist
- Acquisition Integration: Verify the financial impact and integration progress of the Wartner acquisition completed in September 2006.
- Personal Care Segment: Monitor the continued decline in the Personal Care segment (Cutex, Denorex, Prell) and the effectiveness of cost-cutting measures (reduced advertising) in stabilizing contribution margins.
- Debt Service: Review the impact of rising interest rates on variable-rate debt ($363.8 million outstanding) and the effectiveness of interest rate caps in mitigating this risk.
- Legal Exposure: Track the status of the Similasan and OraSure litigation, as adverse outcomes could impact specific product lines (Murine, Wartner).
- Customer Concentration: Assess the risk associated with the top customer representing nearly 25% of sales and the lack of long-term contracts with key manufacturers.